London · Delayed Price · Currency is GBP · Price in GBX Poolbeg Pharma Earnings Call Transcripts
Fiscal Year 2025
-
POLB 001 is advancing toward a key clinical data readout in CRS prevention, supported by strong financials, strategic partnerships, and a robust patent portfolio. The company is also preparing to launch an oral GLP-1 trial for obesity, targeting large and growing markets.
-
POLB 001 is advancing to a phase 2A trial as a first-in-class oral preventative for cancer immunotherapy-induced CRS, with interim data expected in summer 2023. The program targets a significant unmet need, supported by strong preclinical and phase 1 data, FDA orphan drug status, and a robust financial position.
-
POLB001 has received FDA orphan drug designation, unlocking regulatory incentives and exclusivity. A phase 2A trial in multiple myeloma patients will start in H2 2025, with interim data in H1 2026. The program targets a $10B+ market, with strong pharma interest and a robust cash runway.